These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 20582532)

  • 1. Phosphatidylinositol 3-kinase: the oncoprotein.
    Vogt PK; Hart JR; Gymnopoulos M; Jiang H; Kang S; Bader AG; Zhao L; Denley A
    Curr Top Microbiol Immunol; 2010; 347():79-104. PubMed ID: 20582532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class I PI3K in oncogenic cellular transformation.
    Zhao L; Vogt PK
    Oncogene; 2008 Sep; 27(41):5486-96. PubMed ID: 18794883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.
    Kang S; Denley A; Vanhaesebroeck B; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1289-94. PubMed ID: 16432180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and biological characterization of tumor-associated mutations of p110alpha.
    Denley A; Gymnopoulos M; Hart JR; Jiang H; Zhao L; Vogt PK
    Methods Enzymol; 2008; 438():291-305. PubMed ID: 18413256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
    Dbouk HA; Pang H; Fiser A; Backer JM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.
    Geering B; Cutillas PR; Nock G; Gharbi SI; Vanhaesebroeck B
    Proc Natl Acad Sci U S A; 2007 May; 104(19):7809-14. PubMed ID: 17470792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic signaling of class I PI3K isoforms.
    Denley A; Kang S; Karst U; Vogt PK
    Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.
    Rathinaswamy MK; Burke JE
    Adv Biol Regul; 2020 Jan; 75():100657. PubMed ID: 31611073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/AKT signaling pathway and cancer: an updated review.
    Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
    Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
    Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
    Vogt PK; Bader AG; Kang S
    Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras.
    Jimenez C; Hernandez C; Pimentel B; Carrera AC
    J Biol Chem; 2002 Nov; 277(44):41556-62. PubMed ID: 12196526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta and gamma.
    Czupalla C; Culo M; Müller EC; Brock C; Reusch HP; Spicher K; Krause E; Nürnberg B
    J Biol Chem; 2003 Mar; 278(13):11536-45. PubMed ID: 12502714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.
    Graupera M; Guillermet-Guibert J; Foukas LC; Phng LK; Cain RJ; Salpekar A; Pearce W; Meek S; Millan J; Cutillas PR; Smith AJ; Ridley AJ; Ruhrberg C; Gerhardt H; Vanhaesebroeck B
    Nature; 2008 May; 453(7195):662-6. PubMed ID: 18449193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation.
    Denley A; Gymnopoulos M; Kang S; Mitchell C; Vogt PK
    Mol Cancer Res; 2009 Jul; 7(7):1132-8. PubMed ID: 19584261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
    Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
    Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.